I perform surgery on tissue. That tissue is made of cells. And some of those cells — a growing percentage of them as you age — have stopped dividing, stopped contributing, and started actively sabotaging the tissue around them.
These are senescent cells. The longevity community calls them “zombie cells,” which is reductive but not inaccurate. They’re not dead. They’re not alive in any functional sense. They sit in your dermis, your adipose tissue, your fascia, and they secrete a cocktail of inflammatory molecules that degrade the very structures I spend my career trying to preserve and restore: collagen, elastin, extracellular matrix.
If you’ve read my previous articles on peptide therapy and why peptides matter, you already know I believe the future of aesthetic medicine lives at the intersection of surgical precision and molecular biology. Senolytics and senomorphics represent the next chapter of that intersection — and possibly the most consequential one.
This is a long article. It is deliberately technical. I’m writing it because I think the people who choose their surgeon carefully are the same people who want to understand the science at a level deeper than a marketing headline. However, if you prefer to bypass the molecular biology and jump straight to the aesthetic implications, you can click here to skip to What This Means for Your Skin and Your Surgical Outcomes.
Cellular Senescence: The Biology
Every cell in your body has a finite number of times it can divide. This is the Hayflick limit, named after Leonard Hayflick, who demonstrated in 1961 that human fetal fibroblasts divide approximately 40-60 times before permanently exiting the cell cycle. The mechanism behind this limit — telomere shortening — was later elucidated by Elizabeth Blackburn, Carol Greider, and Jack Szostak, earning them the Nobel Prize in 2009.
When a cell reaches this limit, or when it sustains sufficient DNA damage from ultraviolet radiation, oxidative stress, oncogene activation, or chemotherapy, it enters a state called cellular senescence. The cell cycle arrests. The cell doesn’t die. It doesn’t get cleared. It persists.
In small numbers and transient contexts, senescent cells serve a purpose. During wound healing, senescent fibroblasts secrete platelet-derived growth factor AA (PDGF-AA), which stimulates myofibroblast differentiation and promotes efficient wound closure. During embryonic development, senescence contributes to tissue patterning. In tumor suppression, senescence acts as a brake on cells that have acquired oncogenic mutations.
The problem is accumulation. As we age, our immune system becomes less efficient at clearing senescent cells (a process called immunosenescence), and the rate of new senescent cell generation increases. The result is a steadily growing population of cells that have lost their function but retained their capacity to damage.
The Senescence-Associated Secretory Phenotype
The real damage comes not from what senescent cells fail to do but from what they actively produce. In 2008, Judith Campisi’s laboratory at the Buck Institute characterized what they termed the senescence-associated secretory phenotype — the SASP.
The SASP is a complex, dynamic secretome that includes:
- Pro-inflammatory cytokines: Interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-1β — these create chronic, low-grade inflammation, sometimes called “inflammaging”
- Matrix metalloproteinases: MMP-1, MMP-3, MMP-10, MMP-14 — these enzymes directly degrade collagen and elastin fibers in the extracellular matrix
- Chemokines: CCL2, CCL5 — these recruit additional immune cells, amplifying the inflammatory cascade
- Growth factors: TGF-β, VEGF — these disrupt normal tissue homeostasis and promote fibrosis
- Senescence-associated lipids: Identified in 2026 as a novel SASP component that further modifies the dermal matrix
The SASP operates in a paracrine fashion, meaning senescent cells don’t just deteriorate individually — they induce senescence in neighboring healthy cells. This is the bystander effect. One senescent fibroblast in your dermis doesn’t just stop producing collagen; it actively degrades the collagen around it, inflames the tissue, and converts adjacent healthy fibroblasts into senescent ones.
For anyone who has ever wondered why skin aging seems to accelerate — why the changes between 45 and 55 seem more dramatic than between 35 and 45 — this bystander effect is a significant part of the answer. Senescence begets senescence, and the curve is exponential, not linear.
Senolytics: The Case for Killing
Senolytics are compounds that selectively induce apoptosis — programmed cell death — in senescent cells while sparing healthy ones. The term was coined in 2015 by James Kirkland and Tamara Tchkonia at the Mayo Clinic, who published the foundational paper demonstrating that the combination of dasatinib (a tyrosine kinase inhibitor used in leukemia treatment) and quercetin (a plant flavonoid) could selectively eliminate senescent cells in mice, improving physical function and extending healthspan.
The field has expanded dramatically since then. As of mid-2026, there are over 80 human clinical trials investigating senolytic compounds, up from approximately 12 just a few years ago. The Translational Geroscience Network, which Kirkland now leads from Cedars-Sinai (he left Mayo Clinic for a new Center for Advanced Gerotherapeutics), coordinates nearly 90 active clinical trials.
Here are the major players.
Dasatinib + Quercetin (D+Q)
D+Q remains the most clinically advanced senolytic combination. The standard dosing protocol in trials is 100 mg dasatinib plus 1,250 mg quercetin, administered on two consecutive days, repeated every two weeks — an intermittent “hit-and-run” strategy based on the observation that senescent cells, once killed, don’t return quickly.
The clinical data as of 2026 is cautiously encouraging:
STAMINA Pilot Study (2025): A joint Cedars-Sinai/Harvard/Mayo study in older adults at risk for Alzheimer’s disease. Published in eBioMedicine. D+Q was safe and feasible, with statistically significant 2.0-point improvement in Montreal Cognitive Assessment scores among those with the lowest baseline scores. Reductions in TNF-alpha correlated with improved cognition.
Phase 2 Osteoporosis RCT (2024): Published in Nature Medicine. Sixty postmenopausal women. The primary endpoint — reduction in the bone resorption marker CTx — was not met. But bone formation marker P1NP increased significantly (+16% at 2 and 4 weeks), and women with higher senescent cell burden showed enhanced bone formation and density. This study highlights an emerging principle: senolytic efficacy may depend on baseline senescent cell load. Patient selection matters.
Diabetic Kidney Disease (2026): Published in eBioMedicine. D+Q reduced kidney inflammation, senescent cell abundance, macrophage infiltration, and injury in murine diabetic kidney disease while restoring geroprotective factors.
There are also active or recently completed trials in pulmonary fibrosis, frailty, sepsis, mental health disorders (schizophrenia, treatment-resistant depression), childhood cancer survivorship, and a June 2025 glioma trial combining D+Q with fisetin and temozolomide.
The skin-specific data: A 2024 study in Biogerontology demonstrated that D+Q ameliorated skin aging in human dermal fibroblasts through selective elimination of senescent cells and SASP suppression. This is in vitro — not a clinical trial on human skin in vivo — but it establishes the mechanistic basis for what many in the longevity community suspect: systemic senolysis should improve skin quality.
Fisetin
Fisetin is a plant flavonoid found in strawberries, apples, and persimmons. It emerged as a senolytic candidate from Kirkland’s group with a more favorable safety profile than D+Q and, importantly, as a dietary supplement that doesn’t require a prescription.
The clinical data is more limited. The AFFINITY trial (fisetin in older women with gait disturbance) completed data collection in 2019, but comprehensive published results remain elusive. The COVID-FIS trial, testing fisetin in COVID-19 patients, was terminated for futility.
Where fisetin shows genuine promise is topical application. A 2025 study demonstrated that topical fisetin in petrolatum applied to diabetic mice reduced inflammatory markers, increased healthy dermal tissue formation, and decreased fibrosis. Fisetin eliminates senescent dermal fibroblasts through activation of caspases 3, 8, and 9 — a clean apoptotic cascade.
For aesthetics, the topical route may be more relevant than oral supplementation. Direct application to skin bypasses bioavailability issues (fisetin has poor oral absorption) and delivers the compound directly to senescent dermal fibroblasts.
Navitoclax (ABT-263)
Navitoclax is a BCL-2 family inhibitor — it blocks the anti-apoptotic proteins that senescent cells rely on for survival. It is the most potent senolytic in preclinical models but has a serious limitation: dose-dependent thrombocytopenia (platelet destruction). This makes systemic administration in healthy individuals a non-starter.
The breakthrough came in topical form. A study published in 2024-2025 and featured in ScienceDaily in May 2026 demonstrated that topical navitoclax applied to the skin of 24-month-old mice (equivalent to approximately 70 human years) for just five days produced the following:
- Decreased expression of senescence markers p16 and p21
- Upregulation of wound healing pathways: hemostasis, angiogenesis, collagen synthesis, and extracellular matrix organization
- Improved wound closure: 80% wound closure versus 56% in controls by day 24
The researchers specifically noted that topical senolytics could serve as pre-treatment before surgeries — clearing senescent cells from the operative field to improve wound healing and tissue quality.
I will tell you directly: this is the finding in senolytic research that I find most immediately relevant to my practice. If topical senolytic pre-treatment can improve wound healing by 40% in aged tissue — and this holds up in human studies — it would change how I approach surgery in older patients.
Rubedo Life Sciences
Rubedo may be the most important company in this space that you haven’t heard of. Backed by a $75 million Series B led by Andreessen Horowitz’s Bio Fund, Rubedo uses single-cell RNA sequencing and spatial multi-omics to develop highly selective senolytic candidates that minimize off-target cytotoxicity — the precision approach the field has been moving toward.
Their lead compound, RLS-1496, is the first GPX4-modulating senescence-targeting therapy to enter human clinical trials. In May 2025, they dosed the first patient in a Phase 1 trial for plaque psoriasis, skin aging, and inflammatory skin conditions. In October 2025, they received FDA IND clearance for actinic keratosis. They expect approximately 70-subject datasets by the end of 2026.
This is the first dedicated dermatology-focused senolytic clinical trial. It is specifically testing whether clearing senescent cells improves skin.
A second compound, RUBE-103, targets senescent mesenchymal cells in musculoskeletal degeneration, with Phase 1 targeted for the second half of 2026. A systemic formulation of RLS-1496 for broader indications (pulmonary fibrosis, NASH, sarcopenia) has Phase 1 planned for 2027.
Unity Biotechnology — A Cautionary Tale
Unity Biotechnology was the most prominent publicly traded senolytic company. Their lead compound UBX0101 failed in Phase 2 for knee osteoarthritis. Their follow-up, UBX1325 (an intravitreal injection for diabetic macular edema), produced mixed but interesting results — vision gains comparable to aflibercept, with superior performance in a patient subgroup.
Despite positive data, Unity ceased operations in mid-2025. Full workforce reduction in May. Nasdaq delisted in August. Stockholders approved dissolution in September.
The lesson is not that senolytics don’t work. The lesson is that the translational gap between “clears senescent cells” and “produces a clinically meaningful outcome in a specific disease” is wider than the venture capital timeline allows. The science is real. The commercial model for first-generation systemic senolytics hasn’t been solved yet.
Oisín Biotechnologies
Oisín takes a fundamentally different approach — gene therapy. Their Fusogenix Proteo-Lipid Vehicle (PLV) platform delivers genetic payloads that selectively kill senescent cells. They received IND clearance in 2025 and plan Phase 1 trials in 2026. Their preliminary mouse data is striking: 50% increase in muscle size and 100% increase in strength.
Immorta Bio (SenoVax)
SenoVax represents the immunotherapy angle — an autologous dendritic cell therapy that trains the patient’s own immune system to recognize and clear senescent cells. They’ve filed an IND with the FDA for advanced non-small cell lung cancer. In June 2026, they reported doubling mouse lifespan using a combination of SenoVax and regenerative therapy.
This approach — teaching the immune system to do what it used to do before immunosenescence set in — is conceptually elegant and, if it translates, would represent a durable rather than repeated intervention.
FOXO4-DRI: The Peptide That Kills Zombie Cells
FOXO4-DRI deserves its own section because it sits at the intersection of two topics I’ve written about extensively: peptide therapy and cellular aging.
The Mechanism
In senescent cells, the transcription factor FOXO4 is upregulated and localizes within promyelocytic leukemia (PML) nuclear bodies, where it physically binds and sequesters the tumor suppressor protein p53. This interaction is critical: p53, when free, would normally translocate to the mitochondria and initiate apoptosis. By trapping p53 in the nucleus, FOXO4 effectively grants senescent cells immortality — they can’t divide, but they can’t die either.
FOXO4-DRI is a D-retro-inverso peptide — a mirror-image version of a portion of the FOXO4 protein. The “DRI” modification makes it resistant to enzymatic degradation, dramatically increasing its stability in vivo. It competes with endogenous FOXO4 for binding to p53, liberating p53 from its nuclear sequestration. The freed, phosphorylated p53 translocates to the cytoplasm and mitochondria, where it transcription-independently activates BAX, triggers cleaved caspase-3, and induces apoptosis through the p53/BCL-2/Caspase-3 pathway.
A July 2025 paper in Nature Communications solved the structural basis of this interaction using NMR, showing that p53 phosphorylation at serine 15 enhances binding affinity for both FOXO4 and FOXO4-DRI — explaining why the peptide is approximately 11-fold selective for senescent cells over healthy ones.
The de Keizer Study
Peter de Keizer published the landmark FOXO4-DRI paper in Cell in March 2017, working at Erasmus University Medical Center. The results in aged mice treated with FOXO4-DRI (5 mg/kg intravenously, three doses on alternating days):
- Restored fur density — reversal of age-related fur loss
- Improved kidney function — normalized blood markers
- Increased voluntary running activity — improved fitness and vitality
- ~11-fold selectivity for senescent versus non-senescent cells
The fur density result is the one that caught the aesthetic medicine community’s attention. Hair follicle miniaturization and dermal thinning are both associated with senescent cell accumulation in the skin. If clearing those cells restores fur in mice, the implications for human skin and hair quality are obvious.
Recent FOXO4-DRI Research
The science continues to advance:
- February 2025, Communications Biology: FOXO4-DRI induces apoptosis in senescent fibroblasts isolated from keloid tissue. For a surgeon who published a first-author review on keloid pathogenesis, this finding is personally significant. Keloids have long been one of the most frustrating pathologies in plastic surgery — excessive scarring driven by persistent inflammation. If senescent cells in keloid tissue are contributing to that inflammation, and FOXO4-DRI can selectively eliminate them, this opens a potential adjunctive therapy for a condition with limited treatment options.
- January 2026, Frontiers in Bioengineering: FOXO4-DRI suppresses aortic aging and improves aortic function in aged mice.
- 2025, Journal of Medicinal Chemistry: A next-generation peptide inhibitor called CPP-CAND was developed with improved cell permeability and selectivity, suggesting that FOXO4-DRI may be a first-generation prototype with better variants to come.
Availability and Clinical Status
FOXO4-DRI has no regulatory approval anywhere. It has not entered human clinical trials. It is available as a research chemical from peptide synthesis suppliers — a gray area I’ve discussed in my peptide therapy writing.
Peter de Keizer’s company, Cleara Biotech, is not advancing the original FOXO4-DRI molecule but rather a next-generation compound called CL04183. They completed GLP-toxicology studies in rats and non-human primates in 2025 and are progressing toward Phase 1a/1b trials targeting p53-mutant breast and colorectal cancers, with first-in-human dosing targeted for 2027.
The cancer focus is strategic — not because senolytics don’t have broader applications, but because cancer indications offer a faster regulatory pathway and a more defined patient population for initial trials. The longevity and dermatologic applications, if CL04183 proves safe, would follow.
Senomorphics: The Case for Modulation
If senolytics kill senescent cells, senomorphics take a different approach: they suppress the SASP without eliminating the cells themselves. This is pharmacological diplomacy rather than targeted assassination.
The distinction matters because senescent cells, as noted earlier, serve transient beneficial roles in wound healing and tumor suppression. There is a reasonable argument that modulating their destructive output while preserving their useful functions may be safer than killing them outright — particularly in patients who are actively healing.
Rapamycin
Rapamycin, an mTOR inhibitor originally isolated from a soil bacterium on Easter Island (Rapa Nui — hence the name), is the most studied senomorphic compound and arguably the most interesting molecule in geroscience.
The PEARL Trial, published in April 2025, was the first 48-week randomized controlled trial of rapamycin for longevity in healthy adults. One hundred fourteen participants, ages 50-85. The primary endpoint — visceral fat reduction — was not met. Secondary outcomes showed improved lean tissue mass and pain improvements in women taking 10 mg. Overall well-tolerated with adverse events similar to placebo.
The University of Arizona has launched a six-year Phase 3 double-blind RCT — the largest rapamycin trial ever conducted in humans — with $12 million in philanthropic funding, evaluating low-dose rapamycin in adults over 65 for resilience and immune function.
Off-label rapamycin prescribing for longevity is already occurring at scale via telehealth platforms, typically around $65/month. Topical rapamycin has shown modest but measurable improvements in skin senescence markers and clinical appearance. A 2025 review in Aging cautioned that evidence remains moderate and no human trial has demonstrated lifespan extension.
Metformin and the TAME Trial
Metformin — a diabetes drug taken by over 150 million people worldwide — has consistently shown longevity-associated effects in observational data. A May 2025 study in the Journal of Gerontology found metformin users had a 30% lower risk of death before age 90 compared to sulfonylurea users over a 14-15 year follow-up.
The TAME Trial (Targeting Aging with Metformin), designed by Nir Barzilai at Albert Einstein College of Medicine, would be the first clinical trial to use aging itself as an endpoint — a composite of myocardial infarction, heart failure, stroke, cancer, cognitive decline, and death. Three thousand non-diabetic adults aged 65-79, 14 sites, 6 years. The FDA agreed to the trial design, which was itself a regulatory milestone.
As of mid-2026, the trial has still not launched due to persistent funding shortfalls. Estimated cost: $45-75 million. NIA allocated only $5 million. However, ARPA-H’s $144 million PROSPR program (Proactive Solutions for Prolonging Resilience), launched in February 2026, may finally provide the infrastructure. Whether TAME receives direct PROSPR funding remains to be seen.
Newer Senomorphic Compounds
The field is expanding beyond rapamycin and metformin:
Pyrroloquinoline Quinone (PQQ): A 2025 paper in Aging Cell established PQQ as an effective senomorphic that downregulates the full-spectrum SASP by targeting the intracellular protein HSPA8. It alleviated organ degeneration in naturally aged mice while preserving senescent cells — proof of concept that you can neutralize the damage without killing the cell.
Butyrate: A microbiota-derived short-chain fatty acid whose serum levels decline with age. A 2025 Aging Cell paper showed it suppresses senescence in aged T cells and inhibits IL-6/IL-8 SASP factors through mTOR/NF-κB pathway modulation. This creates an interesting connection between gut microbiome health and skin aging — one I expect to hear much more about in the coming years.
Apigenin: A dietary flavonoid found in parsley, celery, and chamomile. A 2025 paper in Advanced Science demonstrated senomorphic activity via ATM/p38MAPK and HSPA8 interactions, with improved physical function and alleviated frailty in prematurely aged animals.
Ruxolitinib: A JAK1/2 inhibitor already FDA-approved as a topical cream (Opzelura) for atopic dermatitis and vitiligo. It suppresses SASP without killing senescent cells by blocking downstream inflammatory signaling. The fact that it’s already in clinical use as a topical skin treatment — with an established safety profile — makes it an intriguing candidate for repurposing as a senomorphic skin therapy.
What This Means for Your Skin and Your Surgical Outcomes
Here is where this connects to the work I do every day.
Collagen and Elastin Degradation
Senescent dermal fibroblasts — the cells responsible for producing and maintaining the structural proteins in your skin — secrete MMPs (matrix metalloproteinases) that directly fragment collagen fibrils. The type III to type I collagen ratio increases. Elastin fibers reorganize and lose their functional architecture. This is the molecular basis of what you see in the mirror: skin that has lost its firmness, its elasticity, its resilience.
Every collagen-stimulating treatment I offer — from Sculptra to microneedling with PRP to surgical tissue repositioning — is working against this ongoing degradation. We build collagen. Senescent cells degrade it. We are, in a very real sense, playing against a stacked deck. Senolytics propose to remove the cards that are stacked against us.
Photoaging and UV Damage
UV radiation accelerates skin senescence through a specific pathway: UV-induced oxidative stress causes leakage of double-stranded DNA from nuclei and mitochondria into the cytoplasm, activating the cGAS-STING signaling pathway and promoting cellular senescence. The senescent cells then produce SASP, driving the visible changes we call photoaging — dyspigmentation, textural changes, fine lines, loss of elasticity.
This is why I tell patients that sun protection isn’t just about preventing sunburn or skin cancer — it’s about preventing the molecular cascade that accelerates cellular senescence. The best anti-aging strategy, at the cellular level, is not adding a serum. It’s not getting a treatment. It’s preventing the UV-induced DNA damage that converts functional fibroblasts into SASP-secreting zombie cells.
Wound Healing and Surgical Recovery
The dual role of senescent cells in wound healing creates a nuanced clinical picture. Transient senescence during the proliferative phase of wound healing is beneficial — those cells secrete growth factors that promote closure. But in aged tissue with a high baseline senescent cell burden, chronic senescence impairs healing.
The topical navitoclax study I mentioned earlier found that clearing senescent cells from aged skin before wounding improved closure by approximately 40%. The researchers explicitly suggested topical senolytic pre-treatment before surgery.
I find it hard to overstate how significant this could be. If validated in human trials, pre-operative topical senolytic application could meaningfully improve healing in the patients who need it most — older patients, patients with UV-damaged skin, patients undergoing revision surgery in previously operated tissue. This is not science fiction. This is Phase 1 clinical trial territory.
Fat Graft Survival and Tissue Quality
Adipose tissue — fat — is one of the primary reservoirs of senescent cells in the body. When I harvest fat for grafting (to the face, to the hands, to the breast), the quality of that tissue matters. Fat from a 30-year-old and fat from a 60-year-old are not the same at the cellular level. The older tissue has a higher senescent cell fraction, a more inflammatory microenvironment, and less regenerative capacity.
If systemic or local senolytic treatment could reduce the senescent cell burden in adipose tissue before harvest, the implications for fat graft survival and quality would be substantial. This hasn’t been studied directly, but the mechanistic basis is sound.
The Accumulation of p16-Positive Melanocytes
A finding with specific aesthetic relevance: the accumulation of p16-positive senescent melanocytes in skin is directly associated with increased facial wrinkling. This isn’t an incidental correlation — p16 is one of the canonical markers of cellular senescence, and melanocytes (the pigment-producing cells) are among the cell types most susceptible to UV-induced senescence. The visual manifestation is both textural (wrinkles) and chromatic (dyspigmentation, age spots).
The Regulatory Landscape
Aging Is Not a Disease — Yet
The FDA does not recognize aging as a formal disease indication. No drug has been approved with aging on its label. Every senolytic and senomorphic compound in clinical trials is being tested for a specific age-related disease — Alzheimer’s, kidney disease, osteoarthritis, pulmonary fibrosis, skin conditions — not for “aging” itself.
This is a regulatory fiction that everyone in the field understands. The diseases being targeted are downstream consequences of the same underlying biological process. But the regulatory framework requires specific disease endpoints, and so that is how the trials are designed.
There are signs of movement. The FDA’s acceptance of the TAME trial’s composite-endpoint design was a precedent — it implicitly acknowledged that a single drug could be tested across multiple age-related conditions simultaneously. ARPA-H’s $144 million PROSPR program, launched in February 2026, represents the first major federal investment treating aging as a tractable biological process. Congressional appropriations language has requested FDA updates on geroscience regulatory pathway progress. And in early 2026, the FDA shifted from requiring two large clinical trials to potentially accepting a single pivotal trial for drug approval — a change that benefits longevity therapeutics significantly.
Peptide Access
For those of you who followed my previous writing on peptide therapy, you know that FDA regulation of compounded peptides has been volatile.
In January 2025, the FDA enforced restrictions on bulk drug substances for compounding pharmacies, pulling many peptides off the market. In February 2026, HHS Secretary Robert F. Kennedy Jr. reversed course, reclassifying 14 of 19 previously restricted peptides back to Category 1. By April 2026, 12 peptides officially came off the Category 2 “do not compound” list, including BPC-157, Thymosin Alpha-1, TB-500, GHK-Cu, and MOTS-C.
The critical distinction: removal from the “do not compound” list does not automatically authorize compounding. The FDA Pharmacy Compounding Advisory Committee (PCAC) must vote on each peptide’s eligibility, with the next review session scheduled for July 23-24, 2026. All reclassified peptides still require a physician prescription and a licensed compounding pharmacy.
FOXO4-DRI exists outside this framework entirely. It is not a Category 1 or Category 2 substance — it is a research chemical available through peptide synthesis suppliers. It has no clinical trial data in humans. Its use constitutes uncontrolled self-experimentation, which I do not recommend.
What No Senolytic Compound Has Yet
No senolytic has FDA approval for any indication. There are over 80 human clinical trials, but only two published randomized controlled trials of systemic senolytic treatment — one showed modest effects (D+Q in osteoporosis), and one showed no effect on frailty or pulmonary function. The field is early. The science is real. The clinical translation is in progress. The gap between “promising preclinical data” and “proven therapeutic” remains significant.
What I Think About All of This
The senolytic hypothesis — that clearing accumulated senescent cells can reverse aspects of aging — is the most intellectually compelling framework I’ve encountered in regenerative aesthetics. It’s not a product pitch. It’s not a brand. It’s a biological mechanism with decades of basic science behind it and a clinical pipeline that is, for the first time, approaching the kind of evidence that changes practice.
I am watching three developments most closely:
Rubedo’s RLS-1496 skin aging trial — because it is the first senolytic study designed specifically for the organ I work on, and because Rubedo’s precision targeting approach addresses the selectivity problem that has limited first-generation senolytics.
Topical senolytic pre-treatment for surgery — because the navitoclax wound healing data, if it translates to humans, would directly improve outcomes for my patients.
FOXO4-DRI and the Cleara next-generation compounds — because the keloid data speaks directly to one of plastic surgery’s most challenging problems, and because the mechanism of selectively unlocking apoptosis in dysfunctional cells is, in my judgment, the most elegant approach in the senolytic toolkit.
I don’t offer senolytic therapy at 360 Plastic Surgery. The evidence isn’t there yet. But I believe it will be within the next several years, and when it arrives, it will be integrated not as a standalone “longevity treatment” but as a foundational component of surgical and aesthetic care — pre-operative tissue optimization, post-operative healing enhancement, and ongoing maintenance of the cellular environment that determines how your skin ages.
The future of aesthetic medicine is not just about what we do to tissue. It’s about the biological condition of the tissue we’re working on.
Dr. Chuma Chike-Obi is a board-certified plastic surgeon and the founder of 360 Plastic Surgery in Austin, Texas. Read his related articles on peptide therapy and why peptides matter.
Written and reviewed by Dr. Chuma Chike-Obi, MD
